Retatrutide cholesterol effects — need advice

Taking the question as asked, rather than the general version of it. The glucagon component looks paradoxical and is not. Glucagon receptor agonism raises energy expenditure and drives hepatic fatty-acid oxidation, and its hyperglycaemic tendency is offset by the GLP-1 arm's insulin secretagogue effect. Net result: intake down from GLP-1/GIP, expenditure up from glucagon, glycaemia neutral or improved. It is a balancing act, and it is why the liver-fat results are the most interesting part of the dataset.

Dr.BariatricHTX said:

The glucagon component looks paradoxical and is not.

Fair, but phase 2 tolerability figures rarely survive contact with phase 3 scale. Triple agonism means three receptor systems generating adverse events, and the dropout column is the one I would read first when the larger trials report.

labquiet_amy said:

Triglycerides dropped by half, HDL barely moved, and my calculated LDL is almost exactly where it started, which is not the outcome I had been…

This is my experience too, for whatever a second data point is worth.

Clinical perspective, offered as context rather than as advice.

Tracking labs for the lipid panel — here's the panel I get every 3 months and why:

• CMP: glucose, electrolytes, kidney function, liver enzymes
• Lipid panel: total cholesterol, LDL, HDL, triglycerides
• A1C: 3-month glucose average
• hsCRP: inflammatory marker
• CBC: blood counts, anemia screening
• B12, folate, iron: nutritional deficiency screening
• TSH, free T4: thyroid monitoring
• Lipase: pancreatic safety check

Total cost with insurance: about $44 copay. Without insurance, request cash-pay pricing from Quest/Labcorp — usually $159.